NAARDEN, the Netherlands and MIAMI - NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a clinical-stage biopharmaceutical company, today announced successful outcomes from its Phase 3 BROOKLYN clinical trial.
The study met its primary endpoint, showing a significant reduction in low-density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH). Obicetrapib, the drug evaluated in the trial, reduced LDL-C by 36.3% at day 84 and 41.5% at day 365 compared to placebo.
The trial involved adult patients whose LDL-C levels were not adequately controlled despite being on maximally tolerated lipid-modifying therapies. The reductions in other biomarkers, such as high-density lipoprotein cholesterol (HDL-C), non-HDL-C, lipoprotein(a), and apolipoprotein B, were also statistically significant and consistent with previous clinical trials.
Dr. John Kastelein, Chief Scientific Officer of NewAmsterdam, highlighted the potential of obicetrapib as a novel, once-daily, oral treatment option for patients who have exhausted existing therapies. The drug was generally well-tolerated with safety results comparable to placebo, and there was no increase in blood pressure among participants.
The company plans to present full results from the BROOKLYN trial at an upcoming medical conference and publish the data in a major medical journal. NewAmsterdam is also conducting additional Phase 3 studies, including BROADWAY, TANDEM, and PREVAIL, as part of a larger clinical development program for obicetrapib.
The BROOKLYN trial's positive results are based on a press release statement from NewAmsterdam. The company expects to report further topline data from its ongoing trials in the coming months, which could support obicetrapib's potential role in addressing unmet needs for LDL-C lowering therapies in cardiovascular disease patients.
In other recent news, NewAmsterdam Pharma Company N.V. is preparing to release top-line data from its Phase 3 BROOKLYN trial. The trial explores the efficacy of obicetrapib, a drug aimed at patients with elevated low-density lipoprotein cholesterol who have not responded adequately to existing treatments. The results of the trial could significantly impact the future of cardiovascular disease treatment and patient care.
In addition to this, TD Cowen has initiated coverage on NewAmsterdam's stock with a Buy rating. The firm's confidence is rooted in the potential of NewAmsterdam Pharma's drug candidate, Obicetrapib. TD Cowen anticipates that the drug could generate over $3 billion in global sales following its projected launch in 2027.
These recent developments, along with upcoming Phase III readouts for Obicetrapib scheduled through 2024 and 2025, underscore a positive outlook for the company. However, it is important to note that these are analyst predictions and should be considered as such.
InvestingPro Insights
As NewAmsterdam Pharma (NASDAQ:NAMS) announces promising results from its BROOKLYN clinical trial, investors and industry watchers are considering the company's financial health and market potential. According to InvestingPro data, NewAmsterdam Pharma holds a market capitalization of $1.7 billion, which is reflective of the market's current valuation of the company's potential.
Despite the clinical success, analysts are cautious about the company's financial outlook. An InvestingPro Tip indicates that analysts do not expect NewAmsterdam Pharma to be profitable this year, which aligns with the reported operating income margin of -2894.14% for the last twelve months as of Q1 2024. This significant operating loss underscores the challenges the company faces in achieving profitability in the near term.
Another InvestingPro Tip reveals that analysts have revised their earnings upwards for the upcoming period, suggesting some optimism in the wake of the trial's success. This optimism may be tempered by the company's revenue growth, which has seen a sharp decline of -88.66% over the last twelve months as of Q1 2024.
Nonetheless, the company's stock has experienced a notable return over the last year, with a year-to-date price total return of 68.85%, highlighting the volatility and potential for growth that some investors may find attractive.
For investors seeking a deeper dive into NewAmsterdam Pharma's financials and future prospects, InvestingPro offers additional tips and insights. Using the coupon code PRONEWS24, readers can get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking access to a comprehensive suite of analytics tools and expert commentary. There are 6 more InvestingPro Tips available that can guide investment decisions regarding NewAmsterdam Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.